Epivir hbv glaxosmithkline

EPIVIR-HBV (lamivudine - solutionoral). Manufacturer: GLAXOSMITHKLINE Approval date: December 8, 1998. Strength(s): 5MGML Epivir HBV Oral tablet 100mg Drug Medication Dosage information. Learn about the Epivir HBV 100mg Tablet GlaxoSmithKline Group of Companies

Epivir-HBV was discovered by BioChem Pharma and licensed to Glaxo Wellcome in 1990. Under the terms of a license agreement, BioChem Pharma will

Epivir-HBV. Bridges to Access. Provided by: GlaxoSmithKline. PO Box 29038. Phoenix, AZ 85038-9038. TEL: 866-728-4368. ALT PHONE: FAX: 1-855-474- 3063 1 infection because the lamivudine dosage in EPIVIR-HBV is subtherapeutic and GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or Under agreement, BioChem Pharma will receive royalties from Glaxo Wellcome on sales of lamivudine for use in both HIVAIDS (3TCEpivirCombivir) and HBV

Generic Epivir-HBV Availability - Drugs.com

It is marketed by GlaxoSmithKline with the brand names Zeffix, Heptovir, Epivir, and Epivir-HBV. Lamivudine has been used for treatment of chronic hepatitis B at Lamivudine (3TC). Trade Name. Zeffix, Epivir-HBV Epivir-HBV US Prescribing Information, GlaxoSmithKline, January 2011. 1. Pereira AS, Kashuba AD,

Epivir-HBV (Lamivudine), Inhibits viral DNA polymerase, GlaxoSmithKline, Philadelphia, PA, FDA Approved 1998. Hepsera (Adefovir Dipivoxil), Inhibits viral 3 Mar 2014 State of Florida DOH Central Pharmacy: EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with